Prostatype Genomics AB (SE:PROGEN)
:PROGEN
PROGEN Stock Chart & Stats
kr0.75
-kr0.32(-6.69%)
At close: 4:00 PM EST
kr0.75
-kr0.32(-6.69%)
Day’s Range― - ―
52-Week Rangekr0.28 - kr3.56
Previous CloseN/A
Volume7.01K
Average Volume (3M)300.11K
Market Cap
kr50.55M
Enterprise Valuekr19.11M
Total Cash (Recent Filing)kr12.93M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding59,189,320
10 Day Avg. Volume460,844
30 Day Avg. Volume300,114
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr1.23M
Bulls Say, Bears Say
Bulls Say
Low Leverage (negligible Debt)Zero/negligible reported debt materially reduces near-term financial risk and preserves flexibility. For a small diagnostics company with recurring cash burn, low leverage lowers bankruptcy risk, eases the burden of interest service, and gives management optionality to fund operations or seek partnerships without heavy fixed obligations.
Focused Proprietary Diagnostic TestA single, clinically focused prognostic test in prostate cancer creates a clear product-market fit and repeatable per-patient revenue streams. Specialization in molecular diagnostics builds domain expertise, supports clinical adoption pathways, and positions the company to benefit from structural demand for precision oncology decision tools over the medium term.
Reduced Cash Burn In 2025Material reduction in operating cash burn year-on-year indicates management is tightening costs or improving revenue conversion. If sustained, this trend lengthens runway, reduces near-term financing reliance and improves prospects for reaching cash-flow break-even, making the business model more durable over the next several months.
Bears Say
Small And Declining Revenue BaseA very small and shrinking revenue base limits scale economics and prevents absorption of fixed lab and R&D costs. Continued declines signal commercialization or market-adoption challenges; without sustained top-line growth the business cannot achieve the unit economics required for long-term sustainability or to fund clinical validation and sales expansion.
Deep, Persistent Negative MarginsConsistently large operating losses and highly negative margins indicate the cost base far outstrips revenue. Persistent negative profitability erodes equity and investor tolerance, forcing reliance on external capital. Without substantial revenue scale or material cost restructuring, margins are unlikely to normalize in the near term.
Ongoing Cash Burn And Financing RelianceRepeated negative cash generation forces dependence on external funding, raising dilution and execution risk. Even with reduced burn in 2025, sustained negative free cash flow means strategic plans hinge on capital access; any disruption to financing channels could curtail commercialization, R&D, or partnership initiatives.
PROGEN FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was kr0.28 and its highest was kr3.56 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is kr50.55M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 13, 2026 which is in 128 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -kr0.397 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.397.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 59,189,320 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -kr0.397 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.907%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in SE:PROGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development of genomic tests aimed at improving the diagnosis and treatment of prostate cancer. The company operates in the healthcare sector, focusing on precision medicine by providing innovative genomic solutions that help clinicians make informed decisions regarding patient management and personalized treatment plans. PROGEN's core product is its proprietary genomic test, which analyzes tumor characteristics to predict disease progression and guide therapeutic choices for prostate cancer patients.